Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: A KASID prospective multicenter cohort study
Intestinal Research — Shin SY, Park SJ, Kim Y, et al. | July 27, 2021
This research sought to evaluate the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). Researchers performed a prospective, observational, multicenter study over 56 weeks in adult patients with moderately to severely active UC who received ADA. Using the Mayo score, clinical response, remission, and mucosal healing were evaluated. The study enrolled a total of 146 patients from 17 academic hospitals. As per the findings, ADA was found to be effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The data indicate that ADA drug level is correlated with the effectiveness of induction therapy. In addition, individuals with better short-term outcomes were predictive of those with an improved long-term response.
Read the full article on Intestinal Research